FDA Status and Ongoing Research Sermorelin had FDA-approved injection products in the 1990s for pediatric growth hormone deficiency and for evaluating GH secretion, but the manufacturer discontinued them and FDA withdrew the NDAs in 2009
Clinical trials on Liraglutide have demonstrated several benefits, including effectively lowering glycemic parameters, weight reduction, and cardiovascular safety in patients with type 2 diabetes mellitus
Patient reported a comfortable and smooth recovery with no complications
Contraindications and Precautions Because BPC 157 remains experimental, certain groups should be particularly cautious
10.1016/j.kint.2016.10.036 113 SzetoH
That said, the right approach depends on your personal health history, current symptoms, and medical needs